Inhibitors of Peptidyl Proline Isomerases As Antivirals in Hepatitis C and Other Viruses
نویسندگان
چکیده
منابع مشابه
Inhibitors of Peptidyl Proline Isomerases As Antivirals in Hepatitis C and Other Viruses
Viruses have small genomes with limited coding capacity. A common strategy by which viral genomes maximize their coding capacity is to express multifunctional proteins that promiscuously interact with various cellular partners to perform an array of essential functions. These interactions often involve flexible, and in some cases intrinsically disordered, viral domains or entire proteins that a...
متن کاملDistribution of Genotypes of B and C Hepatitis Viruses in Guilan Province
Today, chronic viral hepatitis is considered as a public health problem in the world. Totally, 5% of the world population, especially in Asia and Africa suffer from this problem. The prevalence of acute hepatitis in America is 0.1-0.2 percent, 50% of those with hepatitis C (HCV) and 5-10% of them with hepatitis B (HCV) develop chronic hepatitis. Determining HBV and HCV genotypes is important to...
متن کاملImmunophilins and parvulins. Superfamily of peptidyl prolyl isomerases in Arabidopsis.
Immunophilins are defined as receptors for immunosuppressive drugs including cyclosporin A, FK506, and rapamycin. The cyclosporin A receptors are referred to as cyclophilins (CYPs) and FK506- and rapamycin-binding proteins are abbreviated as FKBPs. These two groups of proteins (collectively called immunophilins) share little sequence homology, but both have peptidyl prolyl cis/trans isomerase (...
متن کاملDirectly acting antivirals against hepatitis C virus.
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable pe...
متن کاملStructure-Guided Design Affirms Inhibitors of Hepatitis C Virus p7 as a Viable Class of Antivirals Targeting Virion Release
UNLABELLED Current interferon-based therapy for hepatitis C virus (HCV) infection is inadequate, prompting a shift toward combinations of direct-acting antivirals (DAA) with the first protease-targeted drugs licensed in 2012. Many compounds are in the pipeline yet primarily target only three viral proteins, namely, NS3/4A protease, NS5B polymerase, and NS5A. With concerns growing over resistanc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS Pathogens
سال: 2014
ISSN: 1553-7374
DOI: 10.1371/journal.ppat.1004428